Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 146

1.

Avibactam Sensitizes Carbapenem-Resistant NDM-1-Producing Klebsiella pneumoniae to Innate Immune Clearance.

Ulloa ER, Dillon N, Tsunemoto H, Pogliano J, Sakoulas G, Nizet V.

J Infect Dis. 2019 Mar 29. pii: jiz128. doi: 10.1093/infdis/jiz128. [Epub ahead of print]

PMID:
30923801
2.

Proton-pump inhibitors do not influence clinical outcomes in patients with Staphylococcus aureus bacteremia.

Caffrey AR, Timbrook TT, Ali SR, Nizet V, Sakoulas G.

Therap Adv Gastroenterol. 2019 Mar 21;12:1756284819834273. doi: 10.1177/1756284819834273. eCollection 2019.

3.

Clinical Data on Daptomycin plus Ceftaroline versus Standard of Care Monotherapy in the Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia.

Geriak M, Haddad F, Rizvi K, Rose W, Kullar R, LaPlante K, Yu M, Vasina L, Ouellette K, Zervos M, Nizet V, Sakoulas G.

Antimicrob Agents Chemother. 2019 Apr 25;63(5). pii: e02483-18. doi: 10.1128/AAC.02483-18. Print 2019 May.

4.

Is a Reported Penicillin Allergy Sufficient Grounds to Forgo the Multidimensional Antimicrobial Benefits of β-Lactam Antibiotics?

Sakoulas G, Geriak M, Nizet V.

Clin Infect Dis. 2019 Jan 1;68(1):157-164. doi: 10.1093/cid/ciy557.

PMID:
29986019
5.

The Staphylococcus aureus Two-Component System AgrAC Displays Four Distinct Genomic Arrangements That Delineate Genomic Virulence Factor Signatures.

Choudhary KS, Mih N, Monk J, Kavvas E, Yurkovich JT, Sakoulas G, Palsson BO.

Front Microbiol. 2018 May 25;9:1082. doi: 10.3389/fmicb.2018.01082. eCollection 2018.

6.

Characterization of genetic changes associated with daptomycin nonsusceptibility in Staphylococcus aureus.

Ma Z, Lasek-Nesselquist E, Lu J, Schneider R, Shah R, Oliva G, Pata J, McDonough K, Pai MP, Rose WE, Sakoulas G, Malik M.

PLoS One. 2018 Jun 7;13(6):e0198366. doi: 10.1371/journal.pone.0198366. eCollection 2018.

7.

Impact of cefazolin co-administration with vancomycin to reduce development of vancomycin-intermediate Staphylococcus aureus.

Singh NB, Yim J, Jahanbakhsh S, Sakoulas G, Rybak MJ.

Diagn Microbiol Infect Dis. 2018 Aug;91(4):363-370. doi: 10.1016/j.diagmicrobio.2018.03.020. Epub 2018 Apr 7.

PMID:
29807674
8.

Prevention of High-Level Daptomycin-Resistance Emergence In Vitro in Streptococcus mitis-oralis by Using Combination Antimicrobial Strategies.

Zapata B, Alvarez DN, Farah S, Garcia-de-la-Maria C, Miro JM, Sakoulas G, Bayer AS, Mishra NN.

Curr Microbiol. 2018 Aug;75(8):1062-1067. doi: 10.1007/s00284-018-1491-3. Epub 2018 Apr 12.

PMID:
29651552
10.

Listeria monocytogenes endocarditis: case report, review of the literature, and laboratory evaluation of potential novel antibiotic synergies.

Kumaraswamy M, Do C, Sakoulas G, Nonejuie P, Tseng GW, King H, Fierer J, Pogliano J, Nizet V.

Int J Antimicrob Agents. 2018 Mar;51(3):468-478. doi: 10.1016/j.ijantimicag.2017.12.032. Epub 2018 Jan 11. Review.

11.

Telavancin for refractory MRSA bacteraemia in intermittent haemodialysis recipients.

Britt NS, Tirmizi S, Ritchie DJ, Topal JE, McManus D, Nizet V, Casabar E, Sakoulas G.

J Antimicrob Chemother. 2018 Mar 1;73(3):764-767. doi: 10.1093/jac/dkx437.

12.

Interaction of Antibiotics with Innate Host Defense Factors against Salmonella enterica Serotype Newport.

Sakoulas G, Kumaraswamy M, Kousha A, Nizet V.

mSphere. 2017 Dec 6;2(6). pii: e00410-17. doi: 10.1128/mSphere.00410-17. eCollection 2017 Nov-Dec.

13.

Dissecting Out the Direct Impacts of Large-Scale Antimicrobial Stewardship Interventions on Clinical Outcomes: Can Confounding Be Overcome?

Dilworth TJ, Rose WE, Sakoulas G, Bayer AS.

Clin Infect Dis. 2017 Nov 13;65(11):1956-1957. doi: 10.1093/cid/cix676. No abstract available.

PMID:
29020207
14.

Increased Endovascular Staphylococcus aureus Inoculum Is the Link Between Elevated Serum Interleukin 10 Concentrations and Mortality in Patients With Bacteremia.

Rose WE, Shukla SK, Berti AD, Hayney MS, Henriquez KM, Ranzoni A, Cooper MA, Proctor RA, Nizet V, Sakoulas G.

Clin Infect Dis. 2017 May 15;64(10):1406-1412. doi: 10.1093/cid/cix157. Erratum in: Clin Infect Dis. 2017 Oct 15;65(8):1431-1433.

15.

Evidence To Support Continuation of Statin Therapy in Patients with Staphylococcus aureus Bacteremia.

Caffrey AR, Timbrook TT, Noh E, Sakoulas G, Opal SM, Nizet V, LaPlante KL.

Antimicrob Agents Chemother. 2017 Feb 23;61(3). pii: e02228-16. doi: 10.1128/AAC.02228-16. Print 2017 Mar.

16.

Classical β-Lactamase Inhibitors Potentiate the Activity of Daptomycin against Methicillin-Resistant Staphylococcus aureus and Colistin against Acinetobacter baumannii.

Sakoulas G, Rose W, Berti A, Olson J, Munguia J, Nonejuie P, Sakoulas E, Rybak MJ, Pogliano J, Nizet V.

Antimicrob Agents Chemother. 2017 Jan 24;61(2). pii: e01745-16. doi: 10.1128/AAC.01745-16. Print 2017 Feb.

17.

β-Lactamase Inhibitors Enhance the Synergy between β-Lactam Antibiotics and Daptomycin against Methicillin-Resistant Staphylococcus aureus.

Henson KE, Yim J, Smith JR, Sakoulas G, Rybak MJ.

Antimicrob Agents Chemother. 2016 Dec 27;61(1). pii: e01564-16. doi: 10.1128/AAC.01564-16. Print 2017 Jan.

18.

Cefazolin and Ertapenem, a Synergistic Combination Used To Clear Persistent Staphylococcus aureus Bacteremia.

Sakoulas G, Olson J, Yim J, Singh NB, Kumaraswamy M, Quach DT, Rybak MJ, Pogliano J, Nizet V.

Antimicrob Agents Chemother. 2016 Oct 21;60(11):6609-6618. doi: 10.1128/AAC.01192-16. Print 2016 Nov.

19.

Fosfomycin Enhances the Activity of Daptomycin against Vancomycin-Resistant Enterococci in an In Vitro Pharmacokinetic-Pharmacodynamic Model.

Hall Snyder AD, Werth BJ, Nonejuie P, McRoberts JP, Pogliano J, Sakoulas G, Yim J, Singh N, Rybak MJ.

Antimicrob Agents Chemother. 2016 Sep 23;60(10):5716-23. doi: 10.1128/AAC.00687-16. Print 2016 Oct.

20.

Effects of vancomycin versus nafcillin in enhancing killing of methicillin-susceptible Staphylococcus aureus causing bacteremia by human cathelicidin LL-37.

Le J, Dam Q, Schweizer M, Thienphrapa W, Nizet V, Sakoulas G.

Eur J Clin Microbiol Infect Dis. 2016 Sep;35(9):1441-7. doi: 10.1007/s10096-016-2682-0. Epub 2016 May 27.

21.

New Guidelines Endorse Old Recommendations for Invasive Enterococcal Infections.

Werth BJ, Smith JR, Sakoulas G.

Clin Infect Dis. 2016 Jul 15;63(2):281-2. doi: 10.1093/cid/ciw286. Epub 2016 May 8. No abstract available.

PMID:
27161781
22.

Efficacy of ceftolozane/tazobactam versus levofloxacin in the treatment of complicated urinary tract infections (cUTIs) caused by levofloxacin-resistant pathogens: results from the ASPECT-cUTI trial.

Huntington JA, Sakoulas G, Umeh O, Cloutier DJ, Steenbergen JN, Bliss C, Goldstein EJ.

J Antimicrob Chemother. 2016 Jul;71(7):2014-21. doi: 10.1093/jac/dkw053. Epub 2016 Mar 18.

PMID:
26994090
23.

Bacterial Cytological Profiling (BCP) as a Rapid and Accurate Antimicrobial Susceptibility Testing Method for Staphylococcus aureus.

Quach DT, Sakoulas G, Nizet V, Pogliano J, Pogliano K.

EBioMedicine. 2016 Jan 18;4:95-103. doi: 10.1016/j.ebiom.2016.01.020. eCollection 2016 Feb.

24.

Standard susceptibility testing overlooks potent azithromycin activity and cationic peptide synergy against MDR Stenotrophomonas maltophilia.

Kumaraswamy M, Lin L, Olson J, Sun CF, Nonejuie P, Corriden R, Döhrmann S, Ali SR, Amaro D, Rohde M, Pogliano J, Sakoulas G, Nizet V.

J Antimicrob Chemother. 2016 May;71(5):1264-9. doi: 10.1093/jac/dkv487. Epub 2016 Jan 31.

25.

When sepsis persists: a review of MRSA bacteraemia salvage therapy.

Kullar R, Sakoulas G, Deresinski S, van Hal SJ.

J Antimicrob Chemother. 2016 Mar;71(3):576-86. doi: 10.1093/jac/dkv368. Epub 2015 Nov 12. Review.

PMID:
26565015
26.

Penicillin Binding Protein 1 Is Important in the Compensatory Response of Staphylococcus aureus to Daptomycin-Induced Membrane Damage and Is a Potential Target for β-Lactam-Daptomycin Synergy.

Berti AD, Theisen E, Sauer JD, Nonejuie P, Olson J, Pogliano J, Sakoulas G, Nizet V, Proctor RA, Rose WE.

Antimicrob Agents Chemother. 2015 Nov 2;60(1):451-8. doi: 10.1128/AAC.02071-15. Print 2016 Jan.

27.

Azithromycin Synergizes with Cationic Antimicrobial Peptides to Exert Bactericidal and Therapeutic Activity Against Highly Multidrug-Resistant Gram-Negative Bacterial Pathogens.

Lin L, Nonejuie P, Munguia J, Hollands A, Olson J, Dam Q, Kumaraswamy M, Rivera H Jr, Corriden R, Rohde M, Hensler ME, Burkart MD, Pogliano J, Sakoulas G, Nizet V.

EBioMedicine. 2015 Jun 10;2(7):690-8. doi: 10.1016/j.ebiom.2015.05.021. eCollection 2015 Jul.

28.

Differential Effects of Penicillin Binding Protein Deletion on the Susceptibility of Enterococcus faecium to Cationic Peptide Antibiotics.

Sakoulas G, Kumaraswamy M, Nonejuie P, Werth BJ, Rybak MJ, Pogliano J, Rice LB, Nizet V.

Antimicrob Agents Chemother. 2015 Oct;59(10):6132-9. doi: 10.1128/AAC.00486-15. Epub 2015 Jul 20.

29.

Agranulocytosis with ceftaroline high-dose monotherapy or combination therapy with clindamycin.

Varada NL, Sakoulas G, Lei LR, Chua J.

Pharmacotherapy. 2015 Jun;35(6):608-12. doi: 10.1002/phar.1596. Epub 2015 Jun 3.

PMID:
26037689
30.

Clinical Outcomes of Daptomycin for Vancomycin-resistant Enterococcus Bacteremia.

Moise PA, Sakoulas G, McKinnell JA, Lamp KC, DePestel DD, Yoon MJ, Reyes K, Zervos MJ.

Clin Ther. 2015 Jul 1;37(7):1443-1453.e2. doi: 10.1016/j.clinthera.2015.04.008. Epub 2015 May 15.

PMID:
25982687
31.

In vitro activity of daptomycin in combination with β-lactams, gentamicin, rifampin, and tigecycline against daptomycin-nonsusceptible enterococci.

Hindler JA, Wong-Beringer A, Charlton CL, Miller SA, Kelesidis T, Carvalho M, Sakoulas G, Nonejuie P, Pogliano J, Nizet V, Humphries R.

Antimicrob Agents Chemother. 2015 Jul;59(7):4279-88. doi: 10.1128/AAC.05077-14. Epub 2015 May 11.

32.

Staphylococcus aureus bacteraemia management: where do we stand and where are we going?

Moise PA, Sakoulas G.

Evid Based Med. 2015 Aug;20(4):126. doi: 10.1136/ebmed-2014-110122. Epub 2015 Apr 20. No abstract available.

PMID:
25895528
33.

Heterogeneity of genetic pathways toward daptomycin nonsusceptibility in Staphylococcus aureus determined by adjunctive antibiotics.

Berti AD, Baines SL, Howden BP, Sakoulas G, Nizet V, Proctor RA, Rose WE.

Antimicrob Agents Chemother. 2015 May;59(5):2799-806. doi: 10.1128/AAC.04990-14. Epub 2015 Mar 2.

34.

β-Lactam combinations with daptomycin provide synergy against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium.

Smith JR, Barber KE, Raut A, Aboutaleb M, Sakoulas G, Rybak MJ.

J Antimicrob Chemother. 2015;70(6):1738-43. doi: 10.1093/jac/dkv007. Epub 2015 Feb 1.

35.

Examining the use of ceftaroline in the treatment of Streptococcus pneumoniae meningitis with reference to human cathelicidin LL-37.

Sakoulas G, Nonejuie P, Kullar R, Pogliano J, Rybak MJ, Nizet V.

Antimicrob Agents Chemother. 2015 Apr;59(4):2428-31. doi: 10.1128/AAC.04965-14. Epub 2015 Jan 20.

36.

Daptomycin in combination with other antibiotics for the treatment of complicated methicillin-resistant Staphylococcus aureus bacteremia.

Dhand A, Sakoulas G.

Clin Ther. 2014 Oct 1;36(10):1303-16. doi: 10.1016/j.clinthera.2014.09.005. Epub 2014 Oct 23. Review.

PMID:
25444563
37.

Comment on: Failure of combination therapy with daptomycin and synergistic ceftriaxone for enterococcal endocarditis.

Hall Snyder A, Werth BJ, Barber KE, Sakoulas G, Rybak MJ.

J Antimicrob Chemother. 2015 Apr;70(4):1272-3. doi: 10.1093/jac/dku480. Epub 2014 Nov 27. No abstract available.

PMID:
25433012
38.

Reply to Eschenauer et al.

Kullar R, McKinnell JA, Sakoulas G.

Clin Infect Dis. 2015 Feb 15;60(4):671-2. doi: 10.1093/cid/ciu885. Epub 2014 Nov 3. No abstract available.

39.

Ceftobiprole and ampicillin increase daptomycin susceptibility of daptomycin-susceptible and -resistant VRE.

Werth BJ, Barber KE, Tran KN, Nonejuie P, Sakoulas G, Pogliano J, Rybak MJ.

J Antimicrob Chemother. 2015 Feb;70(2):489-93. doi: 10.1093/jac/dku386. Epub 2014 Oct 9.

PMID:
25304643
40.

Heterogeneity of mprF sequences in methicillin-resistant Staphylococcus aureus clinical isolates: role in cross-resistance between daptomycin and host defense antimicrobial peptides.

Bayer AS, Mishra NN, Sakoulas G, Nonejuie P, Nast CC, Pogliano J, Chen KT, Ellison SN, Yeaman MR, Yang SJ.

Antimicrob Agents Chemother. 2014 Dec;58(12):7462-7. doi: 10.1128/AAC.03422-14. Epub 2014 Oct 6.

41.

Vancomycin plus ceftaroline shows potent in vitro synergy and was successfully utilized to clear persistent daptomycin-non-susceptible MRSA bacteraemia.

Barber KE, Rybak MJ, Sakoulas G.

J Antimicrob Chemother. 2015 Jan;70(1):311-3. doi: 10.1093/jac/dku322. Epub 2014 Aug 13. No abstract available.

PMID:
25125677
43.

Antimicrobial salvage therapy for persistent staphylococcal bacteremia using daptomycin plus ceftaroline.

Sakoulas G, Moise PA, Casapao AM, Nonejuie P, Olson J, Okumura CY, Rybak MJ, Kullar R, Dhand A, Rose WE, Goff DA, Bressler AM, Lee Y, Pogliano J, Johns S, Kaatz GW, Ebright JR, Nizet V.

Clin Ther. 2014 Oct 1;36(10):1317-33. doi: 10.1016/j.clinthera.2014.05.061. Epub 2014 Jul 10.

PMID:
25017183
44.

Potent synergy of ceftobiprole plus daptomycin against multiple strains of Staphylococcus aureus with various resistance phenotypes.

Barber KE, Werth BJ, Ireland CE, Stone NE, Nonejuie P, Sakoulas G, Pogliano J, Rybak MJ.

J Antimicrob Chemother. 2014 Nov;69(11):3006-10. doi: 10.1093/jac/dku236. Epub 2014 Jul 1.

PMID:
24990867
45.

Defining daptomycin resistance prevention exposures in vancomycin-resistant Enterococcus faecium and E. faecalis.

Werth BJ, Steed ME, Ireland CE, Tran TT, Nonejuie P, Murray BE, Rose WE, Sakoulas G, Pogliano J, Arias CA, Rybak MJ.

Antimicrob Agents Chemother. 2014 Sep;58(9):5253-61. doi: 10.1128/AAC.00098-14. Epub 2014 Jun 23.

46.

Evaluation of the novel combination of daptomycin plus ceftriaxone against vancomycin-resistant enterococci in an in vitro pharmacokinetic/pharmacodynamic simulated endocardial vegetation model.

Hall Snyder A, Werth BJ, Barber KE, Sakoulas G, Rybak MJ.

J Antimicrob Chemother. 2014 Aug;69(8):2148-54. doi: 10.1093/jac/dku113. Epub 2014 Apr 28.

PMID:
24777900
47.

Efficacy and safety of daptomycin in patients with renal impairment: a multicenter retrospective analysis.

Kullar R, McClellan I, Geriak M, Sakoulas G.

Pharmacotherapy. 2014 Jun;34(6):582-9. doi: 10.1002/phar.1413. Epub 2014 Mar 21.

PMID:
24658897
48.
49.

Ceftaroline restores daptomycin activity against daptomycin-nonsusceptible vancomycin-resistant Enterococcus faecium.

Sakoulas G, Rose W, Nonejuie P, Olson J, Pogliano J, Humphries R, Nizet V.

Antimicrob Agents Chemother. 2014;58(3):1494-500. doi: 10.1128/AAC.02274-13. Epub 2013 Dec 23.

50.

Nafcillin enhances innate immune-mediated killing of methicillin-resistant Staphylococcus aureus.

Sakoulas G, Okumura CY, Thienphrapa W, Olson J, Nonejuie P, Dam Q, Dhand A, Pogliano J, Yeaman MR, Hensler ME, Bayer AS, Nizet V.

J Mol Med (Berl). 2014 Feb;92(2):139-49. doi: 10.1007/s00109-013-1100-7. Epub 2013 Dec 3.

Supplemental Content

Loading ...
Support Center